Yong Won Choi
Overview
Explore the profile of Yong Won Choi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
755
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Lee Y, Kim Y, Park S, Kang H, Kim J, et al.
Exp Mol Med
. 2024 Dec;
56(12):2631-2641.
PMID: 39617789
Cellular senescence, recognized as a key hallmark of aging, leads to the accumulation of senescent cells in various tissues over time. While the detrimental effects of these cells on age-related...
2.
Heo Y, Kim Y, Lim W, Cho H, Choi Y, Min S
Biochem Biophys Res Commun
. 2024 Nov;
741:151010.
PMID: 39579530
The transcriptional regulation of p53-dependent genes in response to DNA damage is critical for effective DNA repair and cell survival. We previously established that RSF1 (remodeling and spacing factor 1)...
3.
Lee S, Roh J, Park J, Tuncay I, Lee W, Kim J, et al.
Cancer Res Treat
. 2024 Sep;
PMID: 39300929
Purpose: Cancer poses a significant global health challenge, demanding precise genomic testing for individualized treatment strategies. Targeted-panel sequencing (TPS) has improved personalized oncology but often lacks comprehensive coverage of crucial...
4.
Lim N, Goo H, Yoon S, Ahn J, Hong N, Choi Y, et al.
PLoS One
. 2024 Aug;
19(8):e0305616.
PMID: 39178286
Purpose: The management of pressure ulcers (PUs) poses challenges due to their chronic nature and the lack of established conservative treatment methods. In this clinical trial, our objective was to...
5.
Kim R, Kim S, Oh B, Yu W, Kim C, Hur H, et al.
Exp Mol Med
. 2024 Aug;
56(8):1856-1868.
PMID: 39138315
Genomic alterations in tumors play a pivotal role in determining their clinical trajectory and responsiveness to treatment. Targeted panel sequencing (TPS) has served as a key clinical tool over the...
6.
Park S, Lee Y, Choi Y, Lim S, Park S, Kim H, et al.
Cell Rep
. 2024 Mar;
43(3):113912.
PMID: 38446659
In this study, we explore the dynamic process of colorectal cancer progression, emphasizing the evolution toward a more metastatic phenotype. The term "evolution" as used in this study specifically denotes...
7.
Kim T, Choi J, Ahn M, Lee H, Kang S, Choi Y, et al.
BMC Cancer
. 2024 Jan;
24(1):70.
PMID: 38216948
Background: Both first and second-generation EGFR-TKIs are recommended in advanced NSCLC with common EGFR mutations. However, there are few data on the difference in efficacy of EGFR-TKIs based on the...
8.
Lee D, Imran M, Choi J, Park Y, Kim Y, Min S, et al.
Mol Oncol
. 2023 Oct;
18(1):216-232.
PMID: 37854019
Since therapy-induced senescence (TIS) can either support or inhibit cancer progression, identifying which types of chemotherapeutic agents can produce the strongest anti-tumor TIS is an important issue. Here, cyclin-dependent kinase4/6...
9.
Kim T, Choi J, Jeon S, Choi Y, Kwon M, Lee H, et al.
Gastric Cancer
. 2023 Aug;
26(6):1012-1019.
PMID: 37648892
Background: Thromboembolic events (TEEs) are significant adverse events that can cause serious morbidities and mortality in cancer patients receiving chemotherapy. Patients with gastric cancer (GC) treated with palliative chemotherapy have...
10.
Park S, Lee Y, Park S, Lim S, Choi Y, Shin J, et al.
Heliyon
. 2023 Feb;
9(2):e13170.
PMID: 36785830
Senescent tumor cells are nonproliferating tumor cells which are closely related to cancer progression by secreting senescence-related molecules, called senescence-associated secreting phenotypes. Therefore, the presence of senescent tumor cells is...